Sydney Jennings

1 week ago | patientcareonline.com | Sydney Jennings

Aquestive Therapeutics announced that the US FDA has accepted its New Drug Application (NDA) for Anaphylm™, a sublingual film formulation of epinephrine for the treatment of type 1 allergic reactions, including anaphylaxis. The agency has assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026.

1 week ago | patientcareonline.com | Sydney Jennings

At the 2025 European Academy of Allergy and Clinical Immunology (EAACI) Congress, Connect Biopharma presented new data supporting the efficacy of rademikibart, a next-generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, in people with eosinophilic-driven type 2 asthma.

2 weeks ago | patientcareonline.com | Sydney Jennings

The 2025 Revolutionizing Atopic Dermatitis meeting, held in Nashville, TN, has officially come and gone. Patient Care® editors covered several sessions, poster abstracts, and late-breaking data from the meeting, and interviewed multiple presenting authors and experts in the field of dermatology. Below, we recap our complete coverage from the meeting, with direct links to our full articles, video interviews, and Q+A discussions with presenting authors.

2 weeks ago | patientcareonline.com | Sydney Jennings

June 13, 2025Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

2 weeks ago | patientcareonline.com | Sydney Jennings

Results from 2 pivotal clinical studies evaluating DermaSensor—a noninvasive, point-of-care skin cancer assessment device—demonstrate that the tool significantly improves primary care physicians’ (PCPs) ability to detect and manage suspicious skin lesions.